Lonza

© GettyImages/Monty Rakusen

Lonza and Doer Biologics in expression system license deal

By Jane Byrne

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.

Five biggest CDMO deals of the year

Five deals reshaping the CDMO industry this year

By Ben Hargreaves

The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.